Associated Papers
Recurrent resistance mutations to lirafugratinib inform treatment sequencing in FGFR2-driven tumors.
Facchinetti F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Mechanisms of Clinical Resistance to Selective FGFR2 Inhibition by Lirafugratinib.
Ellis H et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2026
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.
Tangermann C et al.
Nature Genetics, 2026
A comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer.
Wang Y et al.
Scientific Data, 2025
Postnatal Progressive Craniosynostosis: An Unusual Case Presentation Leading to Cascade Diagnosis for Multiple Generations.
Ogawa JT et al.
American Journal of Medical Genetics. Part A, 2025
Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study.
Morizane C et al.
Cancer Science, 2025
FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.
Kwon WA
Journal of Korean Medical Science, 2024
Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
Kawano S et al.
Anticancer Research, 2024
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.
Garmezy B et al.
Cancer Research Communications, 2024
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D et al.
Nature, 2022
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.
Cleary JM et al.
Cancer Discovery, 2021
A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers.
Li J et al.
Frontiers in Oncology, 2021
Extremely severe scoliosis, heterotopic ossification, and osteoarthritis in a three-generation family with Crouzon syndrome carrying a mutant c.799T>C FGFR2.
Lin M et al.
Molecular Genetics & Genomic Medicine, 2019
Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases.
Chen H et al.
Elife, 2017
Fibroblast Growth Factor Receptor 2 (FGFR2) Mutation Related Syndromic Craniosynostosis.
Azoury SC et al.
International Journal of Biological Sciences, 2017
Ectrodactyly and Lethal Pulmonary Acinar Dysplasia Associated with Homozygous FGFR2 Mutations Identified by Exome Sequencing.
Barnett CP et al.
Human Mutation, 2016
A novel mutation in FGFR2.
Goos JA et al.
American Journal of Medical Genetics. Part A, 2015
A novel FGFR2 mutation in tyrosine kinase II domain, L617F, in Crouzon syndrome.
Suh YJ et al.
Journal of Cellular Biochemistry, 2014